|
[1] 中华医学会.慢性乙型肝炎防治指南 (2010年版) [J].中国肝脏病杂志, 2011, 3 (1) :40-56.
|
|
[2]Lok AS, McMahon BJ.Chronic hepatitis B:update 2009[J].Hepatology, 2009, 50 (3) :661-662.
|
|
[3]Pawlotsky JM.EASL Clinical Practice Guidelines:management ofchronic hepatitis B[J].J Hepatol, 2009, 50 (2) :243-260.
|
|
[4]Karabay O, Tamer A, Tahtaci M, et al.Effectiveness of lamivudineand interferon-alpha combination therapy versus interferon-alphamonotherapy for the treatment of HBeAg-negative chronic hepatitis Bpatients:a randomized clinical trial[J].J Microbiol Immunol Infect, 2005, 38 (4) :262-266.
|
|
[5]Lampertico P, Vigano M, Manenti E, et al.Low resistance to adefo-vir combined with lamivudine:a 3-year study of 145 lamivudine-resistant hepatitis B patients[J].Gastroenterology, 2007, 133 (5) :1445-1451.
|
|
[6]慢性乙型肝炎联合抗病毒治疗专家共识委员会.慢性乙型肝炎联合抗病毒治疗专家共识[J].中华实验和临床感染病杂志 (电子版) , 2011, 5 (2) :224-233.
|
|
[7]Keeffe EB, Zeuzem S, Koff RS, et al.Report of an internationalworkshop:roadmap for management of patients receiving oral therapyfor chronic hepatitis B[J].Clin Gastroenterol Hepatol, 2007, 5 (8) :890-897.
|
|
[8]慢性丙型肝炎抗病毒治疗专家委员会.慢性丙型肝炎抗病毒治疗专家共识[J].中华实验和临床感染病杂志 (电子版) , 2009, 3 (1) :343-352.
|
|
[9]Wursthorn K, Jaroszewicz J, Zacher BJ, et al.Correlation betweenthe Elecsys HBsAg II assay and the Architect assay for the quantifi-cation of hepatitis B surface antigen (HBsAg) in the serum[J].JClin Virol, 2011, 50 (4) :292-296.
|
|
[10]Thompson AJ, Nguyen T, Iser D, et al.Serum hepatitis B surface anti-gen and hepatitis B e antigen titers:disease phase influences correlationwith viral load and intrahepatic hepatitis B virus markers[J].Hepatolo-gy, 2010, 51 (6) :1933-1944.
|
PDF下载 ( 1100 KB)
本文二维码
下载:
